Small study checks how liver disease affects new drug processing
NCT ID NCT04676425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single 4 mg dose of the drug elpipodect (MK-8189) in 14 people—some with mild or moderate liver problems and some healthy. Researchers measured how much drug stayed in the blood and for how long. The goal was to see if liver impairment changes drug levels, which could guide future dosing. No treatment benefit was tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elpipodect (MK-8189)
What this could lead to
If successful, this study could help doctors decide the right dose of MK-8189 for patients with liver problems.
What could go wrong
This is a very early, small study with only 14 participants. It only looks at how the drug moves through the body, not whether it works for any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami ( Site 0001)
Miami, Florida, 33014, United States
-
ProSciento Inc. ( Site 0002)
Chula Vista, California, 91911, United States